ReviewCurrent cardiology reports2018
Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk.
Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials.Lipids in health and disease · 2019Pooled it
- A Combination ofNutrients · 2021Trial
- Effects of a Novel Nutraceutical Combination (Aquilea ColesterolNutrients · 2019Trial
- Effect of Probiotics ContainingFoods (Basel, Switzerland) · 2025Review
- Pharmacological Mechanisms and Clinical Applications of Curcumin: Update.Aging and disease · 2023Review
- Structural Characterization and Anti-Inflammatory Effects of 24-Methylcholesta-5(6), 22-Diene-3β-ol from the Cultured Marine DiatomMarine drugs · 2023Article
- Advances in Nanofabrication Technology for Nutraceuticals: New Insights and Future Trends.Bioengineering (Basel, Switzerland) · 2022Review
- Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022Review
- Effects of statins on mitochondrial pathways.Journal of cachexia, sarcopenia and muscle · 2021Review
- Nanonutraceuticals: The New Frontier of Supplementary Food.Nanomaterials (Basel, Switzerland) · 2021Review
- Magnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness.Nutrients · 2020Article
- Brassicasterol with Dual Anti-Infective Properties against HSV-1 andBiomedicines · 2020Article
- Alcohol consumption and subclinical atherosclerosis among South Asians: Findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2020Article
- Effects of Curcumin on Microglial Cells.Neurotoxicity research · 2019Review
- Commentary to "The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease".High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Article
- The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of this review is to provide an update on the effects of the dietary supplementation with cholesterol-lowering nutraceuticals and nutraceutical combinations affecting vascular function and CV risk in clinical interventional studies. RECENT
findingsCurrent evidence supports the mild-to-moderate cholesterol-lowering efficacy of red yeast rice, berberine, plant sterols, fibers, and some nutraceutical combinations whereas data on the individual cholesterol-lowering action of other nutraceuticals are either less striking or even inconclusive. There is also promising evidence on the vascular protective effects of some of the aforementioned nutraceuticals. However, except for red yeast rice, clinical interventional studies have not investigated their impact on CV outcomes. Evidence of both cholesterol-lowering and vascular protection is a prerogative of few single nutraceuticals and nutraceutical combinations, which may support their clinical use; however, caution on their uncontrolled adoption is necessary as they are freely available on the market and, therefore, subject to potential misuse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.